Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Sjogren's Syndrome
NCT03926286Phase 1Completed
- Sponsor
- University of Miami
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FMP-30 in Sjogren's syndrome, sponsored by University of Miami. Primary endpoints: Number of participants with reported adverse events and serious adverse events at 7 months and Number of participants with stable microbiome engraftment at 3 months. Started Apr 2019; status: completed.
02
Drugs
FMP-30
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT03926286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926286.